Summit Corp. PLC | Balance Sheet

Fiscal year is February-January. All values GBP Thousands.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
2,030.00
11,265.00
16,304.00
28,062.00
20,102.00
26,858
Total Accounts Receivable
720.00
1,514.00
3,326.00
4,590.00
5,690.00
12,442
Other Current Assets
345.00
2,415.00
1,207.00
685.00
10,098.00
7,433
Total Current Assets
3,095.00
15,194.00
20,837.00
33,337.00
35,890.00
46,733
Net Property, Plant & Equipment
43.00
55.00
83.00
116.00
809.00
616
Intangible Assets
3,493.00
4,147.00
4,137.00
4,134.00
17,263.00
12,418
Total Assets
6,631.00
19,396.00
25,057.00
37,587.00
53,962.00
59,767
Accounts Payable
349.00
1,195.00
716.00
906.00
4,414.00
Other Current Liabilities
1,520.00
2,571.00
2,490.00
9,990.00
14,530.00
Total Current Liabilities
1,869.00
3,766.00
3,206.00
10,896.00
18,944.00
Provision for Risks & Charges
-
-
73.00
85.00
1,641.00
Deferred Taxes
-
664.00
664.00
565.00
2,379.00
Other Liabilities
-
-
5,034.00
29,534.00
21,123.00
Total Liabilities
1,869.00
4,430.00
8,977.00
41,080.00
44,087.00
Common Equity (Total)
485.00
14,966.00
16,080.00
3,493.00
9,875.00
Total Shareholders' Equity
4,762.00
14,966.00
16,080.00
3,493.00
9,875.00
Total Equity
4,762.00
14,966.00
16,080.00
3,493.00
9,875.00
Liabilities & Shareholders' Equity
6,631.00
19,396.00
25,057.00
37,587.00
53,962.00
Preferred Stock (Carrying Value)
5,247.00
-
-
-
-

About Summit Corp.

View Profile
Address
136a Eastern Avenue
Abingdon Oxfordshire OX14 4SB
United Kingdom
Employees -
Website http://summitplc.com
Updated 07/08/2019
Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection. The company was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, United Kingdom.